Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | WOYZEK® Nicotine Inhaler Is Going To Sink Big ShipsFor the first time Buchberger Laboratories Austria is releasing detailed information on its most promising pharmaceutical product candidate – the WOYZEK® Nicotine Inhaler – a cigarette smoking cessation aid for medium and long-term use.
By: Buchberger Laboratories Austria Drugs and therapies currently available for smoking cessation show rather disappointing efficacies. 80-90% of cigarette smokers who attempt to quit fail eventually when applying available drugs and therapies. The WOYZEK® inhaler is particularly addressing this group of smokers. Cigarette smokers are asking for rapid nicotine delivery. WOYZEK® is providing this together with all other sensory effects of cigarettes. The WOYZEK® inhaler will boost the abstinence rate far above the 50 percent mark. Buchberger Laboratories Austria, the company that has developed the WOYZEK® inhaler, is looking for corporate partners and investors who want to join bringing the inhaler to market. Dr. H.M. Buchberger, Founder of Buchberger Laboratories: Find more detailed info at http://www.woyzek.com Buchberger Laboratories Austria mail: P.O. Box 5, A-4470 Enns, Austria Contact Person: Dr. Helmut Buchberger, Managing Director Phone: +46 8 501 64 512 Contact Us: Santa Clara: London: Stockholm: +46 8 501 64 512 Sydney: +61 2 8006-5010 Hong Kong: +852 8198 2405 http://www.buchberger- http://www.woyzek.com # # # About Buchberger Laboratories Austria: Buchberger Laboratories Austria engages in the research, development and commercialization of inhalers, especially nicotine inhalers, and corresponding drug formulations. The company’s lead product candidate WOYZEK® is ready to build commercial prototypes to be tested in clinical trials. End
Account Email Address Disclaimer Report Abuse
|
|